Postinfectious irritable bowel syndrome1 1Abbreviations used in this paper: EC,_; IBS, irritable bowel syndrome; PI, postinfective (Q61960609)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Postinfectious irritable bowel syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

main subject

irritable bowel syndrome

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

Robin C. Spiller

series ordinal

0 references

language of work or name

English

0 references

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

124

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1662-1671

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

Functional bowel disorders and functional abdominal pain

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

7 January 2021

Post-dysenteric colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Irritable bowel syndrome--post salmonella infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Psychometric scores and persistence of irritable bowel after infectious diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

The role of psychological and biological factors in postinfective gut dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Risk of irritable bowel syndrome among asthma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

A cohort study of enteric campylobacter infection in children from birth to two years in Bangui (Central African Republic).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Does non-dysenteric intestinal amoebiasis exist?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Campylobacter Enteritis: Clinical and Epidemiologic Features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Preliminary report: role of peptide YY in defence against diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Cytokine-induced intestinal epithelial hyperpermeability: role of nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Role of serotonin in the immune system and in neuroimmune interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Carbohydrate intolerance after acute gastroenteritis--a disappearing problem in Polish children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Intestinal lactase deficiency and milk drinking capacity in the adult

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Lymphocytic colitis: a clue to an infectious trigger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Quantitative, noninvasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Loperamide treatment of the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Idiopathic bile acid malabsorption--a review of clinical presentation, diagnosis, and response to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Ecological study on the intestinal bacteria flora of patients with diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Abnormal colonic fermentation in irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Oral bacteriotherapy for viral gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Efficacy of probiotic use in acute diarrhea in children: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Small intestinal bacterial overgrowth and the irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Post Salmonella irritable bowel syndrome--5 year review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Prognosis in the irritable bowel syndrome: a 5-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

Level of chronic life stress predicts clinical outcome in irritable bowel syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2803%2900324-X

10.1016/S0016-5085(03)00324-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12761724%20AND%20SRC:MED&resulttype=core&format=json